Preclinical CAR-T Cell Target Safety Biodistribution And Tumor Infiltration Analysis Using The RNAscope ISH Assay
pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
Spatial Transcriptomics Market Share, Industry Trends, Size, Revenue, Demand, Growth Analysis, Top C
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Flagship Biosciences and Leap Therapeutics Announce Partnership and Approach Using RNAscope and Image Analysis for Patient Enrollment
Laboratory Developed Test for Manual and Image Analysis-assisted Pathologist Interpretation
News provided by
Share this article
Share this article
WESTMINSTER, Colo. and CAMBRIDGE, Mass., April 12, 2021 /PRNewswire/ Flagship Biosciences, the leader in data-centric pathology and tissue analysis, and Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced a partnership to use a clinically validated tumor expression assay utilizing RNAscope
® and tissue image analysis. In a poster shared this week at the American Association for Cancer Research (AACR) Annual Meeting 2021, the companies presented data on the validation of a Dickkopf-1 (DKK1) RNAscope chromogenic in situ hybridization (CISH) assay and digital image analysis solution.